急性心筋梗塞における機械的循環支援の使用の変動 心臓発作ショック
Arjun Verma1,2, Nikhil L Chervu1, Justin J Kim1
1Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Heart (British Cardiac Society)
|August 24, 2025
まとめ
急性心筋梗塞 (AMI) と心筋梗塞 (CS) の間では,大動脈内気球ポンプ (IABP) と皮経心室補助器具 (PVAD) の使用に病院間差異がある. 病院の要因はデバイスの選択に影響しますが,リソースの利用はセンター全体で同じです.
科学分野:
- 心臓病科
- 介入心臓科
- 医療サービス研究
背景:
- 急性心筋梗塞 (AMI) に続く心臓ショック (CS) は,高い死亡率を持つ重大な状態です.
- 内動脈バルーンポンプ (IABP) や皮経心室補助装置 (PVAD) を含む機械的循環支援は,AMI CSの管理に不可欠です.
- IABPとPVADの導入のための標準化されたアルゴリズムは欠けていて,治療の潜在的な変化につながります.
研究 の 目的:
- AMI と CS の患者に対する IABP と PVAD の利用における病院間変動を評価する.
- IABPとPVADの病院の好みに関連した制度的要因を特定する.
- 他の機械的なサポート,滞在の長さ,コストなどの二次的な結果を評価する.
主な方法:
- AMIとCSの成人入院に関する2019年全国再入院データベースの分析.
- 患者はIABP,PVAD,および非機械的循環支援グループに分けられました.
- 医療機器の使用における病院間変動を定量化し,病院の特徴 (PCI 容量,安全網の状態) を分析した.
主要な成果:
- 53, 903人の患者のうち,23. 4%がIABP,12. 5%がPVADを受けた.
- 中心レベルの差異はIABPの約13%,PVADの約18%を占めた.
- 高PVADの病院ではPCIの量が高く,セーフティネットの施設になる可能性が高く,高PVADのセンターの患者はECMOまたはLVADの移植へのエスカレーションの調整されたリスクが低い.
結論:
- AMI CSのメカニカル循環支援 (IABP vs PVAD) の選択において,病院間では大きな差異がある.
- 病院の特徴はデバイスの選択に影響しますが,全体的なリソース利用 (滞在期間,費用) は比較可能でした.
- PVADの使用は,さらに機械的なサポートエスカレーションの必要性が減少したとの関連があったが,デバイス選択プロトコルを最適化するためにさらなる研究が必要である.
関連する概念動画
Blood Pressure Imbalances and Circulatory Shock
999
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
999
Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33


